PQ912
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
2
Sites
62
Countries
10
Endpoints
46
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 46 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 9 of 46 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
2
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| SAPHIRSafety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease | PQ912 Alzheimer’s disease | MCI due to AD | Ph 2 | Completed | 23 | Apr 2017 | 1 | |
| VIVA-MINDA Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | PQ912 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Terminated | 22 | Jul 2024 | 3 | results |
| VIVIADA Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD | PQ912 Alzheimer’s disease, MCI / preclinical Alzheimer’s | Study partner/caregiver required | Ph 2 | Completed | 21 | Dec 2023 | 1 |
Showing 1-3 of 3 trials